Technical Analysis for IMNN - Imunon, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
NR7 | Range Contraction | 10.77% | |
Inside Day | Range Contraction | 10.77% | |
Wide Bands | Range Expansion | 10.77% | |
Wide Bands | Range Expansion | 8.27% | |
Up 3 Days in a Row | Strength | 8.27% |
Alert | Time |
---|---|
Possible NR7 | about 3 hours ago |
Rose Above 20 DMA | about 5 hours ago |
20 DMA Support | about 5 hours ago |
60 Minute Opening Range Breakout | about 5 hours ago |
Up 2% | about 5 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
Imunon, Inc. Description
Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Immunotherapy Infectious Diseases Tumor Virotherapy Immunotherapies Human Diseases Virus Platform Technologies Biomolecules Two Platform Technologies
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.0 |
52 Week Low | 0.48 |
Average Volume | 261,091 |
200-Day Moving Average | 0.99 |
50-Day Moving Average | 1.10 |
20-Day Moving Average | 1.44 |
10-Day Moving Average | 1.31 |
Average True Range | 0.17 |
RSI (14) | 56.14 |
ADX | 29.99 |
+DI | 26.16 |
-DI | 16.33 |
Chandelier Exit (Long, 3 ATRs) | 1.49 |
Chandelier Exit (Short, 3 ATRs) | 1.55 |
Upper Bollinger Bands | 1.83 |
Lower Bollinger Band | 1.05 |
Percent B (%b) | 0.5 |
BandWidth | 53.96 |
MACD Line | 0.06 |
MACD Signal Line | 0.08 |
MACD Histogram | -0.0222 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.58 | ||||
Resistance 3 (R3) | 1.58 | 1.53 | 1.56 | ||
Resistance 2 (R2) | 1.53 | 1.49 | 1.53 | 1.55 | |
Resistance 1 (R1) | 1.48 | 1.47 | 1.46 | 1.49 | 1.54 |
Pivot Point | 1.43 | 1.43 | 1.42 | 1.43 | 1.43 |
Support 1 (S1) | 1.39 | 1.40 | 1.36 | 1.39 | 1.34 |
Support 2 (S2) | 1.34 | 1.37 | 1.34 | 1.33 | |
Support 3 (S3) | 1.29 | 1.34 | 1.32 | ||
Support 4 (S4) | 1.30 |